External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

ILC 2026

September 23 - September 26

San Francisco, USA

ilcsymposium.com

We will be contributing to topics related to

Oncology

Add to calendar

Agenda

Medical Materials

12:30 PM

Duration 120mins San Francisco, USA

Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the Phase III lidERA BC clinical trial: Results by menopausal status (encore submission)

Peter Schmid, Charles E. Geyer, Jr., Miguel Martín, Sara A. Hurvitz, Kyung Hae Jung, Mothaffar F. Rimawi, Shigehira Saji, Gustavo Werutsky, Nadia Harbeck, Sherene Loi, Ernesto Pablo Korbenfeld, Isabel Blancas, Chi-Feng Chung, Rena Desai Callahan, Meilin Huang, Miranda Craft, Mona D. Shah, Tanja Badovinac Crnjevic, Pablo Diego Pérez-Moreno, Aditya Bardia

Oncology | Breast Cancer

Notify me

Add to calendar

Coming soon

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.